Symbicort vs Fasenra
A side-by-side look at two respiratory medications advertised on TV. Informational only — not medical advice.
Maintained by TVPills Editorial Team · Site updated November 4, 2026 (not a product-label review)
| Attribute | US Symbicort | US Fasenra |
|---|---|---|
| Generic name | budesonide/formoterol Unverified catalogue summary (Generic name) for Symbicort in US; not checked against current local product information. | benralizumab Unverified catalogue summary (Generic name) for Fasenra in US; not checked against current local product information. |
| Drug class | See official local label Unverified catalogue summary (Drug class) for Symbicort in US; not checked against current local product information. | See official local label Unverified catalogue summary (Drug class) for Fasenra in US; not checked against current local product information. |
| Treats | Asthma, COPD Unverified catalogue summary (Treats) for Symbicort in US; not checked against current local product information. | Severe eosinophilic asthma Unverified catalogue summary (Treats) for Fasenra in US; not checked against current local product information. |
| Category | Respiratory Unverified catalogue summary (Category) for Symbicort in US; not checked against current local product information. | Respiratory Unverified catalogue summary (Category) for Fasenra in US; not checked against current local product information. |
| Manufacturer | AstraZeneca Unverified catalogue summary (Manufacturer) for Symbicort in US; not checked against current local product information. | AstraZeneca Unverified catalogue summary (Manufacturer) for Fasenra in US; not checked against current local product information. |
| Year approved | — Unverified catalogue summary (Year approved) for Symbicort in US; not checked against current local product information. | — Unverified catalogue summary (Year approved) for Fasenra in US; not checked against current local product information. |
| Catalogue warning level | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Symbicort in US; not checked against current local product information. | Safety summary withheld — check official label Unverified catalogue summary (Catalogue warning level) for Fasenra in US; not checked against current local product information. |
| Est. TV ad spend | $120M | $80M |
| Side effects and serious risks | — Unverified catalogue summary (Side effects and serious risks) for Symbicort in US; not checked against current local product information. | — Unverified catalogue summary (Side effects and serious risks) for Fasenra in US; not checked against current local product information. |
Symbicort
Sources and editorial standards
Use the current DailyMed labels to verify approved uses, boxed warnings, and side effects for each medication. Label results can differ by product, strength, and formulation.
Page updated November 4, 2026; the linked resources have not necessarily been reviewed on this date.
Frequently asked questions
Is Symbicort or Fasenra better?
This directory does not compare clinical effectiveness or safety. Listing Symbicort and Fasenra together does not establish shared approved indications, equivalence or suitability as substitutes. Consult the correct local labels and your prescriber.
What's the difference between Symbicort and Fasenra?
The table shows catalogue identification and estimated advertising information for Symbicort and Fasenra, not a verified medical comparison. Medical descriptions, mechanisms and safety summaries are withheld.
Which one spends more on TV ads?
Symbicort has the larger estimated TV advertising budget of the two.